MedTrace Logo

Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

NCT05914961 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2026-02-12

No results posted yet for this study

Summary

ICK-breast is a prospective, multicentric, non-interventional investigator-initiated trial (IIT) that aims to investigate the prognostic value of CRP kinetics in early and advanced or metastatic triple negative breast cancer (TNBC) under immune checkpoint inhibitor (ICI) therapy on pathological complete response (pCR) and event-free survival in early TNBC patients, and objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in advanced or metastatic TNBC.

Conditions

  • TNBC - Triple-Negative Breast Cancer

Sponsors & Collaborators

  • University Hospital Ulm

    collaborator OTHER

  • University Hospital Freiburg

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Tobias Engler, Dr. · Department of Women's Health Tübingen

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2027-04-30
Completion
2035-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05914961 on ClinicalTrials.gov